PRAGUE, Czech Republic — A 0.4-mg/kg bolus dose of tenecteplase (TNKase, Genentech) was associated with functional outcomes and safety similar to those seen with the standard of care, alteplase ...

Thrombolytic agents, including tenecteplase, are generally used within 4.5 hours after the onset of stroke symptoms. Information on whether tenecteplase confers benefit beyond 4.5 hours is limited. We ...

The effects and risks of the use of intravenous thrombolysis between 4.5 and 24 hours after the onset of a posterior circulation ischemic stroke are not well studied. In a trial conducted in China, we ...

ABU DHABI, UAE — A device characterized by the US Food and Drug Administration as safe for the treatment of dysphagia following acute stroke is finally being tested for efficacy in a randomized ...

Racial and ethnic disparities in United States stroke care vary by intervention type at the national and state levels.